Department of Neurophysiology, National Institute of Mental Health and Neurosciences (NIMHANS Deemed University), Bangalore, India.
J Altern Complement Med. 2012 Jun;18(6):612-21. doi: 10.1089/acm.2010.0778.
Studies on alternative medicines for generalized anxiety disorder (GAD) are few. Manasamitra Vataka (an Ayurveda preparation) is explored for its efficacy in patients with GAD with comorbid generalized social phobia.
Seventy-two (72) patients with GAD with comorbid social phobia meeting DSM IV TR criteria, and who were between the ages of 20 and 55 of either sex, participated in the study. They were randomly divided into three treatment groups: Group 1 (n=24) and Group II (n=24) received Manasamitra Vataka tablets (100 mg twice daily for 30 days). Group II, in addition to Manasamitra Vataka, underwent Shirodhara (therapy involving dripping of medicated oil [Brahmi tail] over the forehead) treatment for the first 7 days. Group III (n=24) received clonazepam 0.75 mg daily in divided dose for 30 days. The assessment of the study was done using the Hamilton Anxiety Rating Scale, Beck Anxiety Inventory, Beck Depression Inventory, Epworth Sleepiness Scale (ESS), World Health Organization Quality of Life BREF, and Clinical Global Impression scales (Improvement and Efficacy).
Patients from all the groups showed significant reduction in clinical parameters evaluated. However, improvement in ESS was observed only in Group II. The treatment outcome was comparable between the three groups.
This is the first study conducted on the efficacy of Manasamitra Vataka in anxiety disorders. The results suggest that Manasamitra Vataka is effective in the management GAD with comorbid generalized social phobia. Add-on effect of Shirodhara reduced the daytime sleepiness. Further studies on Manasamitra Vataka need to be carried out to judge its potential as a first-line treatment modality.
针对广泛性焦虑障碍（GAD）的替代医学研究较少。Manasamitra Vataka（一种阿育吠陀制剂）被探索用于治疗同时患有广泛性社交恐惧症的 GAD 患者。
72 名符合 DSM-IV TR 标准的同时患有 GAD 和社交恐惧症的患者参与了这项研究，他们年龄在 20 至 55 岁之间，性别不限。他们被随机分为三组：第 1 组（n=24）和第 2 组（n=24）接受 Manasamitra Vataka 片剂（每天两次，每次 100 毫克，共 30 天）。第 2 组除了接受 Manasamitra Vataka 治疗外，还在前 7 天接受了 Shirodhara（一种将药物油[Brahmi 尾]滴在额头上的治疗方法）治疗。第 3 组（n=24）接受氯硝西泮 0.75 毫克，每日分剂量服用 30 天。使用汉密尔顿焦虑量表、贝克焦虑量表、贝克抑郁量表、Epworth 嗜睡量表（ESS）、世界卫生组织生活质量 BREF 量表和临床总体印象量表（改善和疗效）评估研究。
所有组的患者临床参数均显著降低。然而，仅在第 2 组观察到 ESS 改善。三组的治疗结果相当。
这是首次研究 Manasamitra Vataka 在焦虑障碍中的疗效。结果表明，Manasamitra Vataka 对同时患有广泛性社交恐惧症的 GAD 管理有效。Shirodhara 的附加作用减轻了白天的嗜睡。需要进一步研究 Manasamitra Vataka，以判断其作为一线治疗方法的潜力。
